Overview

Oxcarbazepine 600 mg Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the comparative bioavailability between Oxcarbazepine 600 mg Tablets (test) and Trileptal® 600 mg Tablets (reference) after a single-dose in healthy subjects under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Pharmaceuticals USA
Treatments:
Carbamazepine
Oxcarbazepine